This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

This study has been completed.
Information provided by:
EMD Serono Identifier:
First received: April 12, 2006
Last updated: January 19, 2017
Last verified: January 2017
The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).

Condition Intervention Phase
Parkinson's Disease Dyskinesia Drug: Sarizotan HCl Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Resource links provided by NLM:

Further study details as provided by EMD Serono:

Estimated Enrollment: 360
Study Start Date: July 2002
Estimated Study Completion Date: July 2003

Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or Female
  • The subject is an out-patient
  • Age 30 years or above
  • Dyskinesias present during more than 25% of the waking day
  • Dyskinesias at least moderately disabling
  • Written informed consent

Exclusion Criteria:

  • Pregnancy and/or lactation
  • Participation in another study within the last 30 days
  • Dementia or other psychiatric illness that prevents provision of informed consent
  • History of allergic disorders such as asthma
  • Known hypersensitivity to the study treatment(s)
  • Known hypersensitivity to ACTH
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00314288

  Hide Study Locations
United States, California
Fountain Valley, California, United States
Sunnyvale, California, United States
United States, Florida
Miami, Florida, United States
Tampa, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
United States, Maine
Augusta, Maine, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Missouri
Kansas City, Missouri, United States
United States, New York
Brooklyn, New York, United States
New York, New York, United States
United States, Ohio
Cincinatti, Ohio, United States
Columbus, Ohio, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Rhode Island
Pawtucket, Rhode Island, United States
United States, Tennessee
Memphis, Tennessee, United States
United States, Texas
Houston, Texas, United States
Leuven, Belgium
Sofia, Bulgaria
Edmonton, Canada
Saskatoon, Canada
Vancouver, Canada
Clermont-Ferrand, France
Marseille, France
Nantes, France
Paris, France
Toulouse, France
Bochum, Germany
Dresden, Germany
Leipzig, Germany
Lübeck, Germany
München, Germany
Ulm, Germany
Wiesbaden, Germany
Budapest, Hungary
Gyor, Hungary
Miskolc, Hungary
Coimbra, Portugal
Lisbon, Portugal
Bucaresti, Romania
Constanta, Romania
Targu-Mures, Romania
South Africa
George, South Africa
Plumstead Cape Town, South Africa
Rosebank, South Africa
Sunninghill, South Africa
Wilgers, South Africa
United Kingdom
Cambridge, United Kingdom
Newcastle, United Kingdom
Nottingham, United Kingdom
Sheffield, United Kingdom
Sponsors and Collaborators
EMD Serono
  More Information

Additional Information: Identifier: NCT00314288     History of Changes
Other Study ID Numbers: EMR 62225-006
Study First Received: April 12, 2006
Last Updated: January 19, 2017

Keywords provided by EMD Serono:
Parkinson's Disease
L-dopa-induced dyskinesia

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on September 21, 2017